Aranesp USP listing
Executive Summary
Amgen's Aranesp is accepted by U.S. Pharmacopeia for off-label indication of chemotherapy-associated anemia. Amgen filed a darbepoetin sBLA for the indication Sept. 19. Amgen estimates that 70% of Aranesp's potential market is as a chemotherapy adjunct therapy (1"The Pink Sheet" Jan. 28, p. 29). Aranesp was approved for treatment of anemia in chronic renal failure patients Sept. 18...